The Technical Analyst
OncoCyte Corp [OCX]
Exchange: AMEX Industry: Biotechnology
OncoCyte Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.52% $2.88
America/New_York / 13 mai 2024 @ 13:48
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 38.42 mill |
| EPS: | -3.37 |
| P/E: | -0.850 |
| Earnings Date: | May 14, 2024 |
| SharesOutstanding: | 13.36 mill |
| Avg Daily Volume: | 0.0607 mill |
| RATING 2024-05-13 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.850 | sector: PE 12.30 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.850 | industry: PE -5.55 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 2.73 - 3.02 ( +/- 5.15%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-11 | Broadwood Partners, L.p. | Buy | 2 420 000 | Common Stock, no par value |
| 2024-04-11 | Broadwood Partners, L.p. | Buy | 0 | Common Stock, no par value |
| 2024-04-15 | Broadwood Partners, L.p. | Sell | 0 | Series A Convertible Preferred Stock |
| 2024-04-11 | Riggs Josh | Buy | 3 390 | Common Stock, no par value |
| 2024-04-11 | Arno Andrew | Buy | 33 898 | Common Stock, no par value |
| INSIDER POWER |
|---|
| 37.40 |
| Last 97 transactions |
| Buy: 36 875 696 | Sell: 16 930 326 |
Forecast:
15:27 - $2.87
Live Trading Signals (every 1 min)
Forecast
1: 13:57 - $2.91
Forecast 2: 14:47 - $2.86
Forecast 3: 15:27 - $2.87
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.88 (-0.52% ) |
| Volume | 0.0212 mill |
| Avg. Vol. | 0.0607 mill |
| % of Avg. Vol | 35.01 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For OCX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
OCX
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Latest Press Releases
2024-05-13 08:00:03 - Press Release
Oncocyte To Announce First Quarter 2024 Financial Results
Conference call and webcast on wednesday, may 15, 2024 at 1:30 p.m. pt / 4:30 p.m.
2024-04-12 06:00:07 - Press Release
Oncocyte Reports Full Year 2023 Financial Results
Conference call on friday, april 12, 2024 at 5:00 a.m. pt / 8:00 a.m.
2024-04-12 06:00:00 - Press Release
Oncocyte Reports Full Year 2023 Financial Results
Irvine, calif., april 12, 2024 (globe newswire) -- oncocyte corporation (nasdaq: ocx), a precision diagnostics company, today reported financial results for the year ended december 31, 2023.
2024-04-11 21:48:10 - Press Release
Oncocyte Corporation Announces $15.8 Million Private Placement Of Securities Priced At-the-market Under Nasdaq Rules
Irvine, ca, april 11, 2024 – oncocyte corporation (nasdaq: ocx), (“oncocyte” or the “company”), a precision diagnostics company, today announced that it has entered into definitive securities purchase agreements (the “purchase agreements”) for the purchase and sale of an aggregate of 5,077,387 shares of common stock, at a purchase price of $ 2.
2024-04-11 21:46:00 - Press Release
Oncocyte Corporation Announces $15.8 Million Private Placement Of Securities Priced At-the-market Under Nasdaq Rules
Irvine, calif., april 11, 2024 (globe newswire) -- oncocyte corporation (nasdaq: ocx) (“oncocyte” or the “company”), a precision diagnostics company, today announced that it has entered into definitive securities purchase agreements (the “purchase agreements”) for the purchase and sale of an aggregate of 5,077,387 shares of common stock, at a purchase price of $ 2.9164 per share of common stock, and pre-funded warrants to purchase 342,888 shares of common stock at a purchase price of $2.9163 per pre-funded warrant (the “pre-funded warrants”).
Latest News
2024-04-21 08:45:59 - 24/7 Wall Street
Buffett Grabs More of This Stock, Plus Other Notable Insider Buying
At the end of the previous week, the Oracle of Omaha yet again boosted his stake in a media giant's tracking stocks, even with shares still in retreat.
2024-04-09 16:05:00 - GlobeNewsWire
Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results
IRVINE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will release its fourth quarter and full year 2023 financial results on Friday, April 12, 2024, prior to the U.S. market open.
2023-11-09 09:36:06 - Seeking Alpha
OncoCyte Corporation (OCX) Q3 2023 Earnings Call Transcript
OncoCyte Corporation (NASDAQ:OCX ) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Stephanie Prince - IR, PCG Advisory Josh Riggs - President & CEO Conference Call Participants Mike Matson - Needham Jacob Krahenbuhl - Stephens Vidyun Bais - BTIG Operator Thank you for standing by. My name is Tamika and I will be your conference operator today.
2023-11-03 08:30:00 - GlobeNewsWire
Oncocyte to Announce Third Quarter 2023 Financial Results
Conference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET Conference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET
2023-08-10 12:06:05 - Seeking Alpha
OncoCyte Corporation (OCX) Q2 2023 Earnings Call Transcript
OncoCyte Corporation (NASDAQ:OCX ) Q2 2023 Earnings Conference Call August 10, 2023 8:00 AM ET Company Participants Stephanie Prince - PCG Advisory, IR Josh Riggs - President and CEO Conference Call Participants Mike Matson - Needham & Co. Operator Welcome to the OncoCyte Q2 2023 Earnings Call. All participants will be in listen-only mode.
2023-04-27 16:59:00 - GlobeNewsWire
Oncocyte To Announce First Quarter 2023 Financial Results
IRVINE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it will release its first quarter 2023 financial results on Thursday, May 11, 2023, before U.S. market open.
2023-04-10 22:23:35 - 24/7 Wall Street
Broadwood Partners Now Owns 33.3% of OncoCyte
Fintel reports that Broadwood Partners has filed a 13D/A form with the SEC disclosing ownership of 57.13MM shares of OncoCyte Corp (OCX).
2023-03-29 16:01:00 - GlobeNewsWire
Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call
IRVINE, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it has changed the date of its previously announced earnings conference call. It will now report its fourth quarter and full year 2022 financial results on Monday, April 3, 2023. In conjunction with the release, Oncocyte will host a conference call and webcast that day at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. The company plans to file its Annual Report on Form 10-K on Friday, March 31, 2023.
2023-03-10 12:15:24 - Zacks Investment Research
3 Medical Services Stocks to Buy Amid Industry Challenges
The Zacks Medical - Services industry is growing on digital healthcare adoption. EMBC, INNV and OCX are set to gain the most.
2022-12-16 08:19:50 - Market Watch
Oncocyte cuts 40% of staff
Oncocyte Corp. shares rose 5% in premarket trades after the Irvine, Calif., molecular diagnostics company for the detection of cancer, said it would reduce more than 40% of its workforce "to align its team towards key products that address larger markets.